Literature DB >> 23868911

Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.

Alfred N Fonteh1, Jiarong Chiang, Matthew Cipolla, Jack Hale, Fatimatou Diallo, Alejandra Chirino, Xianghong Arakaki, Michael G Harrington.   

Abstract

Our aim is to study selected cerebrospinal fluid (CSF) glycerophospholipids (GP) that are important in brain pathophysiology. We recruited cognitively healthy (CH), minimally cognitively impaired (MCI), and late onset Alzheimer's disease (LOAD) study participants and collected their CSF. After fractionation into nanometer particles (NP) and supernatant fluids (SF), we studied the lipid composition of these compartments. LC-MS/MS studies reveal that both CSF fractions from CH subjects have N-acyl phosphatidylethanolamine, 1-radyl-2-acyl-sn-glycerophosphoethanolamine (PE), 1-radyl-2-acyl-sn-glycerophosphocholine (PC), 1,2-diacyl-sn-glycerophosphoserine (PS), platelet-activating factor-like lipids, and lysophosphatidylcholine (LPC). In the NP fraction, GPs are enriched with a mixture of saturated, monounsaturated, and polyunsaturated fatty acid species, while PE and PS in the SF fractions are enriched with PUFA-containing molecular species. PC, PE, and PS levels in CSF fractions decrease progressively in participants from CH to MCI, and then to LOAD. Whereas most PC species decrease equally in LOAD, plasmalogen species account for most of the decrease in PE. A significant increase in the LPC-to-PC ratio and PLA2 activity accompanies the GP decrease in LOAD. These studies reveal that CSF supernatant fluid and nanometer particles have different GP composition, and that PLA2 activity accounts for altered GPs in these fractions as neurodegeneration progresses.

Entities:  

Keywords:  lipid metabolism; liquid chromatography; mass spectrometry; minimal cognitive impairment; nanoparticles; neurodegeneration

Mesh:

Substances:

Year:  2013        PMID: 23868911      PMCID: PMC3770101          DOI: 10.1194/jlr.M037622

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  52 in total

Review 1.  Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples.

Authors:  Xianlin Han; Richard W Gross
Journal:  Mass Spectrom Rev       Date:  2005 May-Jun       Impact factor: 10.946

2.  Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway.

Authors:  Gabriel M Simon; Benjamin F Cravatt
Journal:  J Biol Chem       Date:  2006-07-03       Impact factor: 5.157

3.  Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation.

Authors:  N Khaselev; R C Murphy
Journal:  Free Radic Biol Med       Date:  1999-02       Impact factor: 7.376

4.  Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain.

Authors:  D T Stephenson; C A Lemere; D J Selkoe; J A Clemens
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

5.  Critical role of cPLA2 in Aβ oligomer-induced neurodegeneration and memory deficit.

Authors:  Cédric Desbène; Catherine Malaplate-Armand; Ihsen Youssef; Pierre Garcia; Christophe Stenger; Mathilde Sauvée; Nicolas Fischer; Dorine Rimet; Violette Koziel; Marie-Christine Escanyé; Thierry Oster; Badreddine Kriem; Frances T Yen; Thierry Pillot; Jean Luc Olivier
Journal:  Neurobiol Aging       Date:  2011-12-20       Impact factor: 4.673

Review 6.  Lipid signaling in neural plasticity, brain repair, and neuroprotection.

Authors:  Nicolas G Bazan
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

Review 7.  Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration.

Authors:  Akhlaq A Farooqui; Wei-Yi Ong; Lloyd A Horrocks
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2004-03

Review 8.  N-acylation of phosphatidylethanolamine and its biological functions in mammals.

Authors:  Niels Wellner; Thi Ai Diep; Christian Janfelt; Harald Severin Hansen
Journal:  Biochim Biophys Acta       Date:  2012-09-08

9.  Secretory phospholipase A2 type III enhances alpha-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity.

Authors:  Xiaoguang Yang; Wenwen Sheng; Yan He; Jiankun Cui; Mark A Haidekker; Grace Y Sun; James C-M Lee
Journal:  J Lipid Res       Date:  2009-10-05       Impact factor: 5.922

Review 10.  Altered lipid metabolism in brain injury and disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Subcell Biochem       Date:  2008
View more
  29 in total

1.  Loss of Ypk1, the yeast homolog to the human serum- and glucocorticoid-induced protein kinase, accelerates phospholipase B1-mediated phosphatidylcholine deacylation.

Authors:  Beth A Surlow; Benjamin M Cooley; Patrick G Needham; Jeffrey L Brodsky; Jana Patton-Vogt
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

2.  Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging.

Authors:  Danni Li; Clinton Hagen; Ashely R Fett; Hai H Bui; David Knopman; Prashanthi Vemuri; Mary M Machulda; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Neurobiol Aging       Date:  2019-03-18       Impact factor: 4.673

3.  Embedded in the Membrane: How Lipids Confer Activity and Specificity to Intramembrane Proteases.

Authors:  Sandra Paschkowsky; Felix Oestereich; Lisa Marie Munter
Journal:  J Membr Biol       Date:  2017-12-19       Impact factor: 1.843

4.  Combined Sepiapterin Reductase and Methylmalonyl-CoA Epimerase Deficiency in a Second Patient: Cerebrospinal Fluid Polyunsaturated Fatty Acid Level and Follow-Up Under L-DOPA, 5-HTP and BH4 Trials.

Authors:  Michel Mazzuca; Marie-Anne Maubert; Léna Damaj; Fabienne Clot; Marylène Cadoudal; Christele Dubourg; Sylvie Odent; Jean François Benoit; Nadia Bahi-Buisson; Laurence Christa; Pascale de Lonlay
Journal:  JIMD Rep       Date:  2015-03-13

Review 5.  Lipidomic analysis of cerebrospinal fluid by mass spectrometry-based methods.

Authors:  Benoit Colsch; Alexandre Seyer; Samia Boudah; Christophe Junot
Journal:  J Inherit Metab Dis       Date:  2014-12-09       Impact factor: 4.982

6.  Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.

Authors:  Wagner F Gattaz; Leda L Talib; Evelin L Schaeffer; Breno S Diniz; Orestes V Forlenza
Journal:  J Neural Transm (Vienna)       Date:  2013-09-15       Impact factor: 3.575

7.  Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.

Authors:  Pratishtha Chatterjee; Wei L F Lim; Guanghou Shui; Veer B Gupta; Ian James; Anne M Fagan; Chengjie Xiong; Hamid R Sohrabi; Kevin Taddei; Belinda M Brown; Tammie Benzinger; Colin Masters; Stuart G Snowden; Marcus R Wenk; Randall J Bateman; John C Morris; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 8.  Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review.

Authors:  Hussein N Yassine; Meredith N Braskie; Wendy J Mack; Katherine J Castor; Alfred N Fonteh; Lon S Schneider; Michael G Harrington; Helena C Chui
Journal:  JAMA Neurol       Date:  2017-03-01       Impact factor: 18.302

Review 9.  Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review.

Authors:  Barry S Baumel; P Murali Doraiswamy; Marwan Sabbagh; Richard Wurtman
Journal:  Neurol Ther       Date:  2020-12-26

10.  Cerebrospinal fluid lipidomics: effects of an intravenous triglyceride infusion and apoE status.

Authors:  Angela J Hanson; William A Banks; Lisa F Bettcher; Robert Pepin; Daniel Raftery; Suzanne Craft
Journal:  Metabolomics       Date:  2019-12-12       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.